The Compensation and Talent Committee generally approves the target value of annual equity awards for the Company’s executive officers, including each of the Named Executive Officers, at its regularly scheduled meeting in late January or early February of each year, with a grant date to be effective on March 10^th, which is generally following the filing of our Annual Report on Form 10-K for the prior year. Annual equity awards to other company employees are typically approved by our CEO with a grant date of March 10th as well. Additionally, employees may enroll to purchase shares of the Company’s common stock under the terms of the Gilead Sciences, Inc. Employee Stock Purchase Plan, with purchase dates generally in February and August of each year. In special circumstances, including the hiring or promotion of an individual or where the Committee or its authorized delegate determines it is in the best interest of the Company, the Committee or its delegate may approve grants throughout the year, with such grants effective on the 10^th day of each calendar month or at other times determined to be appropriate. The Company may change these practices in the future. The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.

Consistent with the above-described practice, on March 10, 2024, the Committee granted our Named Executive Officers annual equity awards including stock options, restricted stock units and performance shares. This pre-approved grant was made four days before the Company filed a Form 8-K disclosing that Kevin E. Lofton had notified the Board of his decision to retire from the Board, effective as of the conclusion of his term at Gilead’s next annual meeting of stockholders held on May 8, 2024.

Due to this Form 8-K event, as required by SEC rules, the table below sets forth certain information about the annual stock option grants made to our Named Executive Officers.

Name	Grant Date	Number of Securities Underlying the Award		Exercise Price of the Award ($/Sh)		Grant Date Fair Value of the Award		Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information⁽¹⁾
Daniel P. O’Day	March 10, 2024		279,130	$	75.12	$	4,125,011		(2.96)	%
Andrew D. Dickinson	March 10, 2024		87,970	$	75.12	$	1,300,029		(2.96)	%
Johanna Mercier	March 10, 2024		87,970	$	75.12	$	1,300,029		(2.96)	%
Merdad V. Parsey, M.D., Ph.D.	March 10, 2024		89,660	$	75.12	$	1,325,004		(2.96)	%
Deborah H. Telman	March 10, 2024		54,980	$	75.12	$	812,500		(2.96)	%

⁽¹⁾

Reflects the percentage change in the closing market price of our common stock between the trading day ending immediately prior to the Form 8-K filing ($75.94 on March 13, 2024) and the trading day beginning immediately following the disclosure of material nonpublic information ($73.69 on March 15, 2024).

Award Timing Predetermined

true

MNPI Disclosure Timed for Compensation Value

false

Adjustment To PEO Compensation, Footnote [Text Block]

⁽²⁾

The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:

Year	Summary Compensation Table Total for Mr. O’Day		Less: Summary Compensation Table Reported Value of Equity Awards^(a)		Plus: Equity Award Adjustments^(b)		Equals: Compensation Actually Paid to Mr. O’Day
2024	$	23,689,392	$	16,551,827	$	37,647,814	$	44,785,379
2023	$	22,607,690	$	15,615,056	$	8,491,149	$	15,483,783
2022	$	21,621,253	$	14,353,915	$	47,697,917	$	54,965,255
2021	$	19,229,466	$	13,139,064	$	25,394,946	$	31,485,348
2020	$	18,998,095	$	11,513,097	$	8,632,324	$	16,117,322

^(a)	Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
^(b)	The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:

Year	Year End Fair Value of Equity Awards Granted during the Year		Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested during the Year			Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Equity Award Adjustments
2024	$	23,956,270	$	13,333,936		$	(1,033,888	)	$	1,391,496	$	37,647,814
2023	$	12,525,814	$	(2,481,113	)	$	(2,859,625	)	$	1,306,073	$	8,491,149
2022	$	34,153,918	$	14,183,571		$	(1,966,582	)	$	1,327,010	$	47,697,917
2021	$	17,162,219	$	6,011,125		$	707,262		$	1,514,340	$	25,394,946
2020	$	8,885,442	$	(1,693,496	)	$	409,911		$	1,030,467	$	8,632,324

Adjustment to Non-PEO NEO Compensation Footnote [Text Block]

⁽⁴⁾

The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:

Year	Average Reported Summary Compensation Table Total for Other NEOs		Less: Summary Compensation Table Average Reported Value of Equity Awards		Plus: Average Equity Award Adjustments^(a)		Equals: Average Compensation Actually Paid to Other NEOs
2024	$	7,725,458	$	4,828,738	$	11,290,250	$	14,186,970
2023	$	7,588,163	$	4,809,225	$	2,690,199	$	5,469,137
2022	$	7,874,828	$	4,961,052	$	15,268,810	$	18,182,586
2021	$	6,279,776	$	3,625,534	$	7,038,936	$	9,693,178
2020	$	6,616,768	$	3,087,064	$	2,596,731	$	6,126,435

^(a)	The amounts deducted or added in calculating the total average equity award adjustments are as follows:

Year	Average Year End Fair Value of Equity Awards Granted During the Year		Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years			Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year			Average Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value		Total Average Equity Award Adjustments
2024	$	6,878,321	$	4,260,282		$	(282,467	)	$	434,114	$	11,290,250
2023	$	3,955,902	$	(789,322	)	$	(879,498	)	$	403,117	$	2,690,199
2022	$	11,751,514	$	3,365,229		$	(289,102	)	$	441,169	$	15,268,810
2021	$	4,989,853	$	1,461,574		$	271,571		$	315,938	$	7,038,936
2020	$	2,488,166	$	(365,446	)	$	269,145		$	204,866	$	2,596,731